Longevity Health Holdings Announces Exciting Merger
Longevity Health Holdings, Inc., a company dedicated to improving human longevity and healthy aging, has made headlines by announcing its merger with True Health Inc., branded as THPlasma. This merger represents a strategic all-stock transaction that aims to solidify Longevity's position in the growing plasma collection industry. Following the completion of the merger, the combined entity is expected to continue trading on Nasdaq under the ticker symbol 'XAGE.'
Mutual Termination of Previous Deal
In conjunction with this merger, Longevity has also declared the mutual termination of its previous transaction with 20/20 BioLabs. This decisive move indicates a shift in strategy aimed at optimizing growth opportunities in the burgeoning field of plasma collection.
Recent Acquisitions Enrich the Company's Portfolio
The planned merger comes hot on the heels of Longevity's recent acquisitions of Carmell Therapeutics and Elevai Skincare. The Carmell platform leverages plasma-derived growth factors, while Elevai focuses on exosomes sourced from human stem cells. These strategic acquisitions underscore Longevity's commitment to pioneering advancements in regenerative medicine and skincare innovations.
Addressing the U.S. Plasma Shortfall
The U.S. currently provides over 60% of the global plasma supply, yet faces a pressing shortfall in plasma and plasma-derived therapeutics—critical components like immunoglobulins, clotting factors, and albumin. THPlasma aims to bridge this gap by expanding its network of plasma collection centers across the Northeast, further enhancing the country's capacity to meet growing therapeutic demands.
THPlasma's Business Highlights
With a robust strategy to ramp up operations, THPlasma is expected to grow from two plasma collection centers in New Jersey to five by the next fiscal year, expanding further into Pennsylvania as well. The company has established guaranteed sales contracts that project $100 million in annual sales. Notably, management reported that THPlasma achieved cash profitability in FY2024, with projections of significant revenue growth and positive EBITDA moving forward.
Projected Financial Performance
For FY2025, THPlasma anticipates generating $10 million in revenue, with EBITDA at $2 million and net income reaching $1 million. Furthermore, forecasts for FY2026 predict revenue soaring to approximately $32 million, representing around 220% year-over-year growth. EBITDA is projected at $7 million, with a net income of $4 million, reflecting a further 325% growth potential.
Details of the Merger Transaction
The merger values THPlasma at an impressive $59 million, with an additional $20 million in earnouts tied to achieving specified financial benchmarks. Notably, the transaction was assessed at 2.5 times THPlasma's expected FY26 revenue, emphasizing the strategic value both companies bring to the table. Longevity's stock is valued at $3.00 per share, representing a 12% premium compared to a recent closing price.
Leadership Transition Post-Merger
Upon completion of the merger, Mr. Rajiv Shukla, the current Chairman and CEO of Longevity, will take on the role of Executive Chairman, while Mr. George Chi, the Founder and CEO of THPlasma, will be appointed as Co-Chairman and CEO. The board of directors of both companies has unanimously approved the merger, which is expected to finalize in the fourth quarter of the year, pending customary closing conditions.
Implications of the Merger
The merger signifies a pivotal moment for Longevity as it embarks on a growth trajectory that not only enhances shareholder value but also fortifies its market position in a rapidly evolving industry. Both companies have highlighted their shared vision of acceleration in innovation and expansion, opening doors to future M&A opportunities. Their collaborative efforts are anticipated to stimulate growth while delivering substantial value to stakeholders.
About THPlasma
THPlasma is fast becoming a key player in the plasma collection business, managing a network of centers across the Northeastern United States. The company has established long-term contracts with major industry players to ensure guaranteed sales of up to $100 million per year.
About Longevity Health Holdings
Longevity Health Holdings is focused on advancements in longevity and healthy aging, utilizing the latest scientific research in regenerative bio-aesthetics, diagnostics, and nutrition. Their innovative product offerings aim to help individuals look and feel their best at any age.
Frequently Asked Questions
What is the focus of Longevity Health Holdings?
Longevity Health Holdings concentrates on improving human longevity and healthy aging through innovative products and services.
What are the expected benefits of the merger with THPlasma?
The merger is expected to enhance shareholder value, accelerate growth, and open up new market opportunities for both companies.
How many plasma centers does THPlasma plan to operate?
THPlasma plans to expand from two centers in New Jersey to five centers, including Pennsylvania, within the next fiscal year.
What financial performance does THPlasma project?
THPlasma anticipates $10 million in revenue for FY2025 and aims for $32 million in FY2026, indicating strong growth potential.
Who will lead the combined companies post-merger?
Post-merger, Mr. Rajiv Shukla will serve as Executive Chairman, and Mr. George Chi will take the role of Co-Chairman and CEO.
